On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.

In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...

BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today provided its strategic ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

Caribou Biosciences, Inc. data from phase 1 ANTLER study is expected in 1H 2025. Click here to find out why I'm neutral on ...